Gerresheimer decisively continued on its profitable growth course in the financial year 2023 with an organic revenue growth of 10.4 percent and a strong adjusted EBITDA growth of 17.5 percent.
- Organic revenue growth in 2023: +10.4 percent
- Organic adjusted EBITDA growth in 2023: +17.5 percent
- Favourable product mix boosts profitability
- High order backlog and global capacity expansion secure profitable growth for the years ahead
Revenues reached EUR 1.99 billion (2022: EUR 1.82 billion), the adjusted EBITDA EUR 404.5 million (2022: EUR 354.2 million). The adjusted EBITDA margin improved organically by 120 basis points to 20.8 percent (2022: 19.6 percent) and reflects a higher share of innovative and customized solutions in the company’s product mix, including for sensitive biopharmaceuticals.
Gerresheimer’s high level of solution expertise and broad product portfolio allows it to benefit from global mega-trends in the pharma and biotech markets. In 2023, for example, the company secured further orders for syringes, pens and auto-injectors for GLP-1 drugs. The positive development of the operating business, the high order backlog and the current expansion of international production capacities mean that Gerresheimer is ideally positioned to continue its profitable growth in the years ahead.
“Our strong results in 2023 underpin Gerresheimer’s successful transformation as part of our formula g strategy process,” said Dietmar Siemssen, CEO of Gerresheimer AG. “The market has recognized that Gerresheimer is positioned very differently today. Innovative systems and solutions have enabled us to gain new orders from existing customers and expand our customer base overall.”
To read the full report click here.